Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01956305 · ClinicalTrials.gov registry record · Phase 1
Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01956305 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 48 participants.
The verdict
NCT01956305, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
DS-7309 is being developed for the treatment of type 2 diabetes mellitus (T2DM). This will be a randomized, placebo-controlled, blinded, sequential, multiple ascending dose study to assess the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of multiple doses of DS-7309 in subjects with T2DM.
Interventions
- DRUG placebo
- DRUG Metformin
- DRUG DS-7309
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01956305
The ClinicalTrials.gov registry entry for NCT01956305 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01956305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01956305 about?
NCT01956305 is a clinical study titled "Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study". DS-7309 is being developed for the treatment of type 2 diabetes mellitus (T2DM). This will be a randomized, placebo-controlled, blinded, sequential, multiple ascending dose study to assess the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of multiple doses of DS-7309 in subj...
What is the current status of trial NCT01956305?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-09. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01956305?
The interventions under investigation include: placebo (DRUG), Metformin (DRUG), DS-7309 (DRUG).
Who is sponsoring clinical trial NCT01956305?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.